Jane Street Group LLC grew its holdings in Compugen Ltd. (NASDAQ:CGEN) by 20.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 65,721 shares of the biotechnology company’s stock after acquiring an additional 11,192 shares during the quarter. Jane Street Group LLC owned about 0.13% of Compugen worth $252,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wells Fargo & Company MN increased its holdings in shares of Compugen by 424.5% in the 2nd quarter. Wells Fargo & Company MN now owns 7,526 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 6,091 shares during the last quarter. LPL Financial LLC acquired a new stake in shares of Compugen during the second quarter worth $43,000. D. E. Shaw & Co. Inc. acquired a new stake in shares of Compugen during the second quarter worth $45,000. Morgan Stanley raised its holdings in shares of Compugen by 2.1% during the second quarter. Morgan Stanley now owns 1,035,175 shares of the biotechnology company’s stock worth $3,975,000 after acquiring an additional 21,368 shares during the period. Finally, Taylor Frigon Capital Management LLC raised its holdings in shares of Compugen by 11.5% during the second quarter. Taylor Frigon Capital Management LLC now owns 760,424 shares of the biotechnology company’s stock worth $2,920,000 after acquiring an additional 78,278 shares during the period. Institutional investors and hedge funds own 29.95% of the company’s stock.
Shares of NASDAQ:CGEN opened at $4.17 on Friday. Compugen Ltd. has a 12 month low of $2.00 and a 12 month high of $4.50. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.38 and a current ratio of 5.38. The company’s fifty day simple moving average is $4.09 and its 200 day simple moving average is $3.68.
A number of equities research analysts recently commented on CGEN shares. ValuEngine lowered shares of Compugen from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Zacks Investment Research upgraded shares of Compugen from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Thursday.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Featured Article: What are the benefits of investing in REITs?
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.